Mitopure discovered to slow down aging of immune system – Longevity.Technology

Timeline, a Swiss consumer biotech company, has announced the successful completion of its immune aging clinical study, MitoImmune, revealing groundbreaking results that could revolutionize the way we approach aging. The study focused on Mitopure, a proprietary form of Urolithin A, and its impact on re-energizing T-cells, crucial for fighting infections and age-related diseases.

The study, conducted in collaboration with the Georg-Speyer-Haus Institute and the Buck Institute, enrolled 50 middle-aged adults in a randomized, placebo-controlled trial over a four-week intervention with Mitopure. The results were impressive, with the primary endpoints of increasing youthful naive CD8 T-cells and improving mitochondrial activity in these cells successfully met with Mitopure intervention compared to placebo. Secondary endpoints, including reduction of inflammaging, were also achieved.

“This research opens a totally new approach to directly impact our immune cells and help restore their functionality during aging,” said Chris Rinsch, Co-Founder and President of Timeline. Dr. Eric Verdin, CEO and President of the Buck Institute, called the findings “groundbreaking” and emphasized the potential of targeted mitochondrial interventions like Mitopure to counter the age-related decline of the immune system.

In addition to the MitoImmune study, Timeline has partnered on two new clinical trials with leading research institutions to further explore the impact of Mitopure on healthy aging. These studies will investigate the potential of Mitopure to improve metabolic health and manage oxidative stress in middle-aged adults, with implications for age-related metabolic decline and cancer patients.

Earlier this year, Timeline secured $66 million in funding from investors including Nestlé and L’Oréal Group, highlighting the growing interest and support for their innovative research in the field of immune aging and healthy longevity.